美國研究指出施打兩劑COVID-19疫苗,不足以對抗Omicron病毒

In Market Shorts
December 16, 2021
COVID-19新變異毒株Omicron在各國快速流竄,傳染力比Delta更強,引發公衛專家擔憂。美國研究發現,若只施打兩劑COVID-19疫苗,保護力不足以對抗Omicron病毒,必須追加補強針,才能建立充分免疫力。路透社、CNBC報導,根據麻省總醫院(Massachusetts General Hospital)、哈佛(Harvard)和麻省理工學院(MIT)發表的研究報告(尚未同儕審查),從血液檢測結果來看,無論是施打兩劑莫德納(Moderna)或輝瑞/BioNTech疫苗,或施打單劑嬌生疫苗,其血清對於Omicron變異株的中和能力極低,甚至不存在(low to absent)。不過,再追加一劑疫苗後,受試者所產生的中和抗體,即可有效中和Omicron變異株。對此,白宮首席醫學顧問佛奇12月15日表示,民眾只需施打現有疫苗的作為補強,就能有效對抗Omicron病毒,不需等待專為Omicron病毒株開發的新疫苗。佛奇提到,就算只施打兩劑輝瑞/BioNTech疫苗,仍能提供相當大的保護,防止重症發生,預防住院治療的有效率達70%。他強調,未接種疫苗者須盡快打疫苗,尤其是在Omicron變異株流行地區,如果已完整接種疫苗,則應施打補強針。

場外式黃金/白銀交易的風險:
Service relating to Over-the-counter (OTC) Gold Bullion/Silver trading is provided by MOL. OTC Gold/Silver Bullion trading carries a high degree of risk and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. OTC Gold/Silver Bullion is not regulated by the Securities and Futures Commission (""SFC"") and therefore trading OTC Gold/Silver Bullion will not be subject to rules or regulations promulgated by the SFC. Before deciding to trade OTC Gold/Silver Bullion you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain losses in excess of your deposited fund or even more in extreme circumstances and therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading OTC Gold/Silver Bullion, and seek advice from an independent financial advisor if you require.